Robert Eisenbach

Cooley advised Momofuku Goods, a brand of restaurant-grade pantry staples, on its $17.5 million Series A financing led by Siddhi Capital. The new funding will allow Momofuku to expand product offerings and support its growing operations, which includes scaling its team and marketing efforts.

“We spent a decade testing and developing our pantry essentials, ensuring that they were up to the standards we uphold in our restaurants,” David Chang, celebrity chef and founder of Momofuku restaurant group, said in a press statement. “With this investment, I’m looking forward to bringing even more flavor to home cooks’ kitchens.” Founded by the team behind Momofuku restaurants, Momofuku Goods offers a range of products, including chili crunch oil, air-dried noodles, soy sauce, rice vinegar and seasoned salts that are sold online and in more than 2,000 retail stores.

Winston Gu and Yvan-Claude Pierre led the Cooley team, which also included Len Jacoby, JP Oleksiuk, Jonathan Rivinus, Robert Eisenbach, Joyce Kim, Chris Chynoweth, Andrew Mettry, Bomin Kim and Noah Belsky.

Cooley advised GrowFlow, a business-to-business software as a service (SaaS) platform dedicated to helping customers grow their cannabis businesses, on its agreement to sell to Dama Financial, the nation’s largest provider of access to banking and payment solutions for the cannabis industry. Partners Dave Young and Steven Dunst led the Cooley team advising GrowFlow.

Cooley advised Singapore-headquartered Genesis MedTech International on its acquisition of the Chocolate Touch drug-coated balloon from TriReme Medical, a wholly owned subsidiary of Singapore-listed QT Vascular. The Chocolate Touch drug-coated balloon is the world's first balloon catheter that combines therapeutic agent delivery with the next generation of controlled dilation angioplasty technique for the treatment of peripheral vascular diseases. Cooley partners Lila Hope and Matthew Bartus led the team advising Genesis MedTech.

Fate Therapeutics in its global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets. The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates.

Under the terms of the agreement, Janssen will receive $50 million in cash and $50 million from the purchase by Johnson & Johnson Innovation  JJDC, Inc. of newly issued shares of the Company’s common stock at a price per share of $31.00. Janssen is also eligible to receive payments of up to  $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones, plus double-digit royalties on worldwide commercial sales of products targeting the antigens.

Cooley was selected as debtors’ counsel for Quirky, an invention startup company. Cooley is working with potentially interested parties to establish a stalking-horse bidder for the Quirky assets, including assets related to the Quirky online community and the Quirky name. Quirky's affiliate Wink has entered into an agreement with Flextronics International USA for the sale of assets related to the Wink business at a purchase price of $15 million.